DS-5010 is a highly selective and potent RET (ret proto-oncogene) kinase inhibitor in late preclinical development. RET rearrangements and activating mutations are associated with several types of cancer,
In a separate agreement, XOMA has granted Novartis a license to its intellectual property covering the use of IL-1 beta targeting antibodies in the treatment of cardiovascular disease.
CF PharmTech, founded by seasoned industry experts and entrepreneurs with a successful track record in the US pharmaceutical industry, is focused on the development, manufacturing and commercialization of
Mavenclad is the first oral short-course treatment to provide efficacy across key measures of disease activity in patients with highly active RMS, including disability progression, annualized relapse rate
The Humira biosimilar can now be used in Europe for treating rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, pediatric plaque psoriasis, adult and adolescent hidradenitis
Ribociclib is now licensed for use in Europe as a first-line treatment in combination with an aromatase inhibitor in postmenopausal women with hormone receptor positive, human epidermal growth
At 12 months, APL-2, administered monthly via intravitreal injection, showed a 29% (p=0.008) reduction in the rate of GA lesion growth compared to sham. With every other month
"New drugs like this one to treat advanced types of cancer are vital to ensure three in four people survive their disease by 2035.” – Dr Nigel Blackburn,
The study also did not meet its key secondary endpoints. Adverse events were generally balanced between Ace-ER and placebo and safety was consistent with previously released Ace-ER data.
Dravet Syndrome is a rare pediatric disease and lifelong form of epilepsy, which starts in the first year of life with frequent or prolonged seizures. Currently, the company
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.